MacroGenics (MGNX) News Today $3.57 -0.24 (-6.30%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Notice to MacroGenics, Inc. (MGNX) Shareholders: Grabar Law Office Investigates Claims on Your BehalfNovember 14 at 4:47 AM | markets.businessinsider.comFY2024 Earnings Estimate for MacroGenics Issued By B. RileyMacroGenics, Inc. (NASDAQ:MGNX - Free Report) - Analysts at B. Riley issued their FY2024 earnings estimates for shares of MacroGenics in a research report issued on Wednesday, November 6th. B. Riley analyst M. Mamtani expects that the biopharmaceutical company will post earnings of $0.00 per sharNovember 11, 2024 | marketbeat.comMacroGenics (NASDAQ:MGNX) Upgraded to Buy at StockNews.comStockNews.com upgraded MacroGenics from a "sell" rating to a "buy" rating in a research report on Sunday.November 10, 2024 | marketbeat.comLeerink Partnrs Predicts Increased Earnings for MacroGenicsNovember 10, 2024 | americanbankingnews.comFY2024 EPS Estimates for MacroGenics Lifted by HC WainwrightNovember 9, 2024 | americanbankingnews.comFY2024 EPS Estimates for MacroGenics Boosted by AnalystMacroGenics, Inc. (NASDAQ:MGNX - Free Report) - Research analysts at HC Wainwright raised their FY2024 earnings estimates for shares of MacroGenics in a research note issued on Wednesday, November 6th. HC Wainwright analyst R. Burns now forecasts that the biopharmaceutical company will post earniNovember 8, 2024 | marketbeat.comLeerink Partnrs Forecasts Increased Earnings for MacroGenicsMacroGenics, Inc. (NASDAQ:MGNX - Free Report) - Leerink Partnrs upped their FY2024 EPS estimates for MacroGenics in a report issued on Wednesday, November 6th. Leerink Partnrs analyst J. Chang now expects that the biopharmaceutical company will post earnings of ($1.24) per share for the year, upNovember 8, 2024 | marketbeat.comAttention Macrogenics, Inc. (MGNX) Shareholders: Grabar Law Office Investigates Potential Claims on Your BehalfNovember 8, 2024 | markets.businessinsider.comMacroGenics downgraded to market perform by JMP, price target removedNovember 7, 2024 | msn.comMacroGenics (MGNX) was downgraded to a Hold Rating at JMP SecuritiesNovember 7, 2024 | markets.businessinsider.comMacroGenics (NASDAQ:MGNX) Downgraded to Market Perform Rating by JMP SecuritiesJMP Securities cut MacroGenics from an "outperform" rating to a "market perform" rating in a report on Thursday.November 7, 2024 | marketbeat.comMacroGenics’ Transition Phase: Balancing Potential and Uncertainty Amid Leadership and Pipeline DevelopmentsNovember 7, 2024 | markets.businessinsider.comMacrogenics Inc (MGNX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic DevelopmentsNovember 7, 2024 | finance.yahoo.comMacroGenics’ Strategic Moves and Promising Pipeline Justify Buy RatingNovember 7, 2024 | markets.businessinsider.comMacroGenics (MGNX) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | msn.comMacroGenics to Participate in Upcoming Investor ConferencesNovember 6, 2024 | globenewswire.comMacroGenics' (MGNX) "Neutral" Rating Reiterated at HC WainwrightHC Wainwright reissued a "neutral" rating and set a $4.00 price objective on shares of MacroGenics in a research report on Wednesday.November 6, 2024 | marketbeat.comMacroGenics, Inc. (MGNX) Q2 2024 Earnings Call TranscriptNovember 5, 2024 | seekingalpha.comMacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial ResultsNovember 5, 2024 | globenewswire.comMacrogenics Earnings PreviewNovember 4, 2024 | benzinga.comEarnings To Watch: Macrogenics Inc (MGNX) Reports Q3 2024 ResultNovember 4, 2024 | finance.yahoo.comMacroGenics (NASDAQ:MGNX) Stock Rating Lowered by StockNews.comStockNews.com lowered MacroGenics from a "hold" rating to a "sell" rating in a report on Saturday.November 2, 2024 | marketbeat.comMacroGenics announces CEO Koenig to step downOctober 31, 2024 | markets.businessinsider.comMacroGenics, Inc.: MacroGenics Announces Leadership TransitionOctober 30, 2024 | finanznachrichten.deMacroGenics Co-Founder Koenig Stepping Down as President, CEOOctober 30, 2024 | marketwatch.comMacroGenics Announces CEO Transition Amidst Strong GrowthOctober 30, 2024 | msn.comMacroGenics (MGNX) Scheduled to Post Earnings on TuesdayMacroGenics (NASDAQ:MGNX) will be releasing earnings after the market closes on Tuesday, November 5, Zacks reports.October 30, 2024 | marketbeat.comMacroGenics Announces Leadership TransitionOctober 30, 2024 | globenewswire.comMacroGenics Announces Date of Third Quarter 2024 Financial Results Conference CallOctober 29, 2024 | globenewswire.comMacroGenics, Inc. (NASDAQ:MGNX) Receives Average Rating of "Hold" from BrokeragesShares of MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) have been assigned a consensus recommendation of "Hold" from the eleven analysts that are presently covering the company, Marketbeat.com reports. Seven analysts have rated the stock with a hold recommendation, three have assigned a buy reOctober 26, 2024 | marketbeat.comMacroGenics (NASDAQ:MGNX) Stock Rating Upgraded by StockNews.comStockNews.com raised MacroGenics from a "sell" rating to a "hold" rating in a report on Friday.October 25, 2024 | marketbeat.comMacroGenics (MGNX) Receives a Rating Update from a Top AnalystOctober 24, 2024 | markets.businessinsider.comMacroGenics to Sell Margenza Cancer Drug for $40 MillionOctober 23, 2024 | marketwatch.comMacroGenics in $40M deal with TerSera Therapeutics for sale of MargenzaOctober 23, 2024 | markets.businessinsider.comMacroGenics (MGNX) Receives a Buy from JMP SecuritiesOctober 23, 2024 | markets.businessinsider.comMacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®October 22, 2024 | businesswire.comDimensional Fund Advisors LP Lowers Stake in MacroGenics, Inc. (NASDAQ:MGNX)Dimensional Fund Advisors LP trimmed its position in MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 14.5% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 898,497 shares of the biopharmaceutical comOctober 10, 2024 | marketbeat.comMillennium Management LLC Grows Stock Holdings in MacroGenics, Inc. (NASDAQ:MGNX)Millennium Management LLC boosted its position in MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 3,473.7% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 3,312,672 shares of the biopharmaceutical company's stock after acquiring an additional 3,219,977 shares dOctober 7, 2024 | marketbeat.comMarshall Wace LLP Grows Stake in MacroGenics, Inc. (NASDAQ:MGNX)Marshall Wace LLP grew its position in MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 1,689.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 658,007 shares of the biopharmaceutical company's stock after purchasingOctober 4, 2024 | marketbeat.comRenaissance Technologies LLC Sells 231,000 Shares of MacroGenics, Inc. (NASDAQ:MGNX)Renaissance Technologies LLC lowered its stake in MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 32.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 484,027 shares of the biopharmaceutical company's stock aOctober 3, 2024 | marketbeat.comMacroGenics, Inc. (NASDAQ:MGNX) Receives Average Rating of "Hold" from AnalystsShares of MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) have been assigned an average recommendation of "Hold" from the eleven analysts that are currently covering the stock, MarketBeat reports. Seven equities research analysts have rated the stock with a hold recommendation, three have assigneOctober 1, 2024 | marketbeat.comFrazier Life Sciences Management L.P. Has $12.80 Million Stock Holdings in MacroGenics, Inc. (NASDAQ:MGNX)Frazier Life Sciences Management L.P. lifted its stake in shares of MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 21.8% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 3,010,727 shares of the biopharmaceutical company's stock after buying anSeptember 29, 2024 | marketbeat.comHere's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash WiselySeptember 26, 2024 | finance.yahoo.comArmistice Capital LLC Grows Stock Position in MacroGenics, Inc. (NASDAQ:MGNX)Armistice Capital LLC raised its holdings in shares of MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 150.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,000,000 shares of the biopharmaceutical companySeptember 26, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against MacroGenics, Inc. - MGNXSeptember 25, 2024 | prnewswire.comShareholders of MacroGenics, Inc. Should Contact The Gross Law Firm Before September 24, 2024 to Discuss Your Rights – MGNXSeptember 24, 2024 | globenewswire.comMGNX Investors Have Opportunity to Join MacroGenics, Inc. Fraud Investigation with the Schall Law FirmSeptember 24, 2024 | tmcnet.comMGNX Deadline in 1 Day: Kessler Topaz Meltzer & Check, LLP Reminds MacroGenics, Inc. (MGNX) Investors of Filing Deadline in Class Action LawsuitSeptember 24, 2024 | markets.businessinsider.comHagens Berman Alerts MacroGenics (MGNX) Investors to Today's Lead Plaintiff Deadline in Securities Class ActionSeptember 24, 2024 | globenewswire.comMacroGenics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MGNXSeptember 24, 2024 | prnewswire.com Get MacroGenics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Buffett’s Selling Out: Is Your 401(k) About to Get Wiped Out? (Ad)Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too? Click Here For Your Free Guide MGNX Media Mentions By Week MGNX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MGNX News Sentiment▼0.930.55▲Average Medical News Sentiment MGNX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MGNX Articles This Week▼108▲MGNX Articles Average Week Get MacroGenics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Repare Therapeutics News Puma Biotechnology News CARGO Therapeutics News IGM Biosciences News Cullinan Therapeutics News Phibro Animal Health News 89bio News Prothena News Pliant Therapeutics News Autolus Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MGNX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MacroGenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MacroGenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
